Company profile
Dare Bioscience, Inc.
NASDAQ: DARE · Healthcare · Biotechnology
#869 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
36DFH 36DQ 33GM 39SS 48
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), Piotroski F · ↓ growth stability, return on equity
Methodology →Revenue TTM
$1.2M
Rev growth YoY (TTM)
+4366.5%
Net income (FY)
-$13.4M
Employees
23
as of 2026-08-21
Market cap
$12.1M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.0M$1.0M2025
Net income-$13.4M-$13.4M2025
Operating income-$13.6M-$13.6M2025
Total assets$32.5M$32.5M2025
Liabilities$29.6M$29.6M2025
Equity$2.8M$2.8M2025
Revenue trend
FY2014 – FY2025 · USD
FY14
FY14
FY16
FY22
FY22
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License And Collaboration Revenues100%
By geography
Not disclosed.
The read
What is Dare Bioscience, Inc.’s revenue?
Dare Bioscience, Inc. booked $1.0M in FY2025 revenue, growing 10429% year over year — faster than 99% of Healthcare companies we track, at a -1300.7% net margin.
Peers · Healthcare
First Choice Healthcare Solutions, Inc.26DOrgenesis Inc.——Marijuana Company of America, Inc.——Sintx Technologies, Inc.35DEhouse Global, Inc.——60 Degrees Pharmaceuticals, Inc.34DNeighbors
San Diego →Key facts
CEOSabrina Martucci Johnson
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: DARE
Employees23
IPO date2014-04-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.